ICON Plc

ICON Plc ICON is a global provider of outsourced clinical research development services to the pharmaceutical, biotechnology, and medical device industries.

We help our clients accelerate the development of life-saving drugs that improve patients' quality of life.

ICON’s Patient Centred Outcomes team delivered strong progress in 2025.– Over 45 specialists across Europe and North Ame...
31/03/2026

ICON’s Patient Centred Outcomes team delivered strong progress in 2025.
– Over 45 specialists across Europe and North America
– Twelve peer‑reviewed papers and two webinars
– Methodological depth across COA strategy, psychometrics, qualitative research and COA data analysis

Clear, operationally robust patient‑centred evidence remains our focus for 2026. Learn more: https://ow.ly/qaXe50YytNS

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally ...
31/03/2026

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GMP) or United States Pharmacopeia (USP).

In this blog we look at each practice set and weigh their relative advantages and disadvantages. We’ll explore why incorporating both is now considered best practice for early phase trials. https://ow.ly/70Ni50Yzc3C

Scientific rigor continues to shape payer expectations, and offers an important forum for advancing those standards. I...
30/03/2026

Scientific rigor continues to shape payer expectations, and offers an important forum for advancing those standards. ICON will be at booth #1412 to discuss approaches to robust evidence generation, real world data methodologies and outcomes research that meet the needs of managed care decision makers.

Our team will be in Nashville to share how validated analytical frameworks and transparent study design can strengthen formulary evaluations and support more consistent, data driven access decisions. https://ow.ly/Hwsk50YuBHL

At ICON, we believe that the most valuable learning comes from shared experience.Our teams recently came together for a ...
30/03/2026

At ICON, we believe that the most valuable learning comes from shared experience.

Our teams recently came together for a Clinical Research Associate Masterclass led by Hristina Gogova and Loreta Ivanova. The session offered a unique opportunity to explore site operations from a different perspective, bringing to life the day to day realities of the CRA role.

Through real world insights, practical guidance, and open discussion, the session highlighted the critical connection between CRAs and site teams. It reinforced how strong collaboration and shared understanding can elevate the quality and impact of clinical research.

A special thank you to Yordan Zahariev for organising and leading this initiative, and to Hristina and Loreta for sharing your expertise and experience with such openness.

Many therapeutic areas lack complete head to head data. Our whitepaper outlines how network meta analysis constructs a c...
30/03/2026

Many therapeutic areas lack complete head to head data.

Our whitepaper outlines how network meta analysis constructs a connected evidence base by integrating direct and indirect comparisons, provided studies share a suitable common comparator and meet transitivity criteria.

It also shows how this structure improves the precision of effect estimates while supporting consistent, reproducible methodologies for HTA and policy decisions.

Explore the whitepaper: https://ow.ly/TTzc50YwbaZ

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical d...
27/03/2026

Latest issue out now.

Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials?

Join thousands of subscribers who have discovered the convenience of our free monthly publication by signing up today: https://ow.ly/rIU250Yz0hL.

Compiled and collated by ICON’s Regulatory Intelligence Team and delivered monthly to your inbox, it provides the overview you need, with convenient links to the detailed sources.

Stay ahead of the dynamic and ever-changing world of clinical trial regulations by signing up today!

China’s biotech sector continues its strong growth trajectory, creating new opportunities for global innovation. In this...
27/03/2026

China’s biotech sector continues its strong growth trajectory, creating new opportunities for global innovation. In this latest BioXconomy analysis, Yao Zhong, Vice President and General Manager for ICON China Mainland and Hong Kong, shares insights that help contextualise what this momentum means for R&D partnerships and future development strategies. https://ow.ly/Uoxk50Ywi4S

Bioanalytical strategy is central to successful biosimilar development. Our latest spotlight explores how scientific adv...
27/03/2026

Bioanalytical strategy is central to successful biosimilar development. Our latest spotlight explores how scientific advancements are helping teams strengthen comparability, improve accuracy and accelerate development timelines.
Read the full report: https://ow.ly/Qlsr50YyEj2

26/03/2026

When head to head trials are limited, decision makers still need reliable comparisons across multiple treatments.

Our new whitepaper outlines how NMA connects available evidence to generate precise, transparent and policy relevant results. It also examines MAIC, STC and ML NMR and offers guidance on selecting the right approach for your research context.

Learn more in the full paper: https://ow.ly/TTzc50YwbaZ

With increasing approvals across Asia and beyond, ADCs remain one of the most dynamic areas in oncology innovation.ICON’...
26/03/2026

With increasing approvals across Asia and beyond, ADCs remain one of the most dynamic areas in oncology innovation.
ICON’s new publication highlights the critical elements of regulatory engagement, dose optimisation and collaborative review initiatives shaping the path to market.
Read the analysis: https://ow.ly/sANX50YnYEw

90% of biotech leaders in China expect AI and digital tools to accelerate R&D within the next two years.ICON’s 2025 Chin...
26/03/2026

90% of biotech leaders in China expect AI and digital tools to accelerate R&D within the next two years.
ICON’s 2025 China biotech survey report explores how digital technologies are reshaping R&D and clinical trial design.

9 out of 10 respondents expect AI‑enabled innovation to significantly accelerate development timelines.

Access the full report: https://ow.ly/8sQ750YiEP1

How to navigate EU MAA Regulations and Registration. Regulatory legislation in China differs substantially from that of ...
25/03/2026

How to navigate EU MAA Regulations and Registration.

Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter the market it is critical to assess the correct pathway, analyse the clinical, non-clinical and quality data package for potential gaps before applying for an MAA with the EMA.

Download our whitepaper to learn about how to navigate the complexities of drug approval in the EU, EMA’s Policy 0070 and transparency requirements and considerations that can help ensure the success of your submission plan and regulatory strategy. Get your copy today https://ow.ly/NjgL50Xz28G

Address

South County Business Park, Leopardstown
Dublin
18

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+35312912000

Website

Alerts

Be the first to know and let us send you an email when ICON Plc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ICON Plc:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category